CABA News and Press, Cabaletta Bio Inc. From 04/20/24

2024-04-20 06:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-21 13:53:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ: CABA ) just reported results for the fourth quarter of 2023. Cabaletta Bio reported earnings per share of -46 cents. This was below the analyst esti...

2024-03-21 11:01:39 ET More on Cabaletta Bio Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward Cabaletta gets FDA orphan drug status for systemic sclerosis drug Read the full article on Seeking Alpha For further details see: Cabaletta ...

2024-03-21 07:08:19 ET More on Cabaletta Bio Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward Cabaletta gets FDA orphan drug status for systemic sclerosis drug Cabaletta Bio gains on FDA fast-track tags for lead asset Seeking Alpha’...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up...

2024-03-20 11:54:00 ET More on Cabaletta Bio Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward Cabaletta Bio gains on FDA fast-track tags for lead asset Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Caba...

PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administrat...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-02-18 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...